natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 18 for use in treating a chronic viral infection in an animal; optionally wherein said animal is human. The pharmaceutical composition for use according to claim 22, wherein said chronic viral infection is selected from the group consisting of: HIV, HBV and HCV. 
Protutijelo ili njegov fragment za vezanje, za uporabu prema patentnom zahtjevu 14, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 14, naznačen/o time, da se kod kronične virusne infekcije radi o virusnoj infekciji odabranoj iz skupine koju čine HIV, HBV i HCV.
In the case where such a siloxane is implemented in addition to the additives introduced in steps (a) and (b) according to the process of the invention, this siloxane may be advantageously dosed at 200 to 1000 ppm, preferably at 400 to 600 ppm, and most preferably at 500 ppm. 
Postupak prema zahtjevu 24, naznačen time da se siloksan dozira sa 200 do 1000 ppm, poželjno sa 400 do 600 ppm, te najpoželjnije 500 ppm. Postupak prema zahtjevu 24 ili 25, naznačen time da se siloksan uvodi u postupak nakon koraka (b).
said stabilizing agent is 2% w/v sucrose; and said surfactant is 0.004% w/v polysorbate-20; and wherein said therapeutic peptibody comprises a structure set out in Formula I, Formula I: [(X1)a-F1-(X2)b]-(L1)c-WSPd wherein: 
navedeni stabilizator je 2 % w/v saharoza; i navedena površinski aktivna materija je 0.004% w/v polisorbat-20; ili navedeni pH puferski agens je 20 mM histidin i pH 5.0;
The method of claim 10, wherein the L1 signaling information includes FEC type information of the PLP data in the data slice packets. 
Postupak prema zahtjevu 10, gdje L1 signalna informacija obuhvaća FEC tip informacije PLP podataka u paketima podatkovnih komada,
and its salts of addition with pharmaceutically acceptable organic and inorganic acids and bases; 
C,-Cu alkinil-skupina i fenil-skupina; te njegove adicijske soli s farmaceutski prihvatljivim organskim i anorganskim kiselinama i lužinama.
a benzimidazyl group, optionally mono- or polysubstituted with a linear or branched C1-C6 alkyl group, or 
benzimidazilna skupina koja može biti mono ili višesupstituirana ravnolančastom ili razgranatom C1-C6 alkilnom skupinom, ili
an amino group of the formula: 
Datum podnošenja europske prijave patenta:
1.538 or a pharmaceutically acceptable salt, hydrate or rotomer thereof. 
[image] [image] [image] ili njegova farmaceutski prihvatljiva sol, hidrat ili rotomer.
(AMENDED) An in-vitro method of inhibiting JAK-3, ROCK or Aurora kinase activity in a biological sample, comprising the step of contacting said biological sample with: a composition according to claim 26; or 
Postupak inhibiranja aktivnosti JAK-3, ROCK ili Aurora kinaze in vitro, u biološkom uzorku, naznačen time što se sastoji u koraku stavljanja navedenog biološkog uzorka u kontakt:
is —(CR6R7)n(5–6 membered heterocyclic), wherein said 5–6 membered heterocyclic group is optionally substituted with at least one R4 group; 
R' je «(CR*R'),(5-6-eročlani heterocikl), gdje je navedena 5-6-eročlana heterociklička skupina izborno supstituirana s najmanje jednom skupinom R';
For example, WO 02/076211 describes an oral dosage formulation comprising nicotine. 
Na primjer, WO 02/076211 opisuje formulaciju oralne doze koja sadrži nikotin.
Fig. 4 shows a broken view when the closing system is in its closed position in which the mobile brewing head support 7 and the lower frame 6 tightly enclose a capsule confinement space. 
Slika 4 prikazuje pogled na razotkriven sustav kada je taj sustav za zatvaranje u svojem zatvorenom položaju u kojemu nosač pomične glave za pripremanje napitka 7 i donji okvir 6 čvrsto obuhvaćaju prostor za omedivanje čahure.
The therapeutic nanoparticle of any one of embodiments 1-24, wherein the hydrophobic acid is a bile acid. The therapeutic nanoparticle of embodiment 32, wherein the bile acid is selected from the group consisting of chenodeoxycholic acid, ursodeoxycholic acid, deoxycholic acid, hycholic acid, beta-muricholic acid, cholic acid, lithocholic acid, an amino acid-conjugated bile acid, and combinations thereof. 
Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što je hidrofobna kiselina žučna kiselina, po mogućnosti gdje se žučnu kiselinu bira iz skupine koju čine henodeoksikolna kiselina, ursodeoksikolna kiselina, deoksikolna kiselina, hikolna kiselina, B-murikolna kiselina, kolna kiselina, litokolna kiselina, žučna kiselina konjugirana s aminokiselinom, te njihove kombinacije.
According to the invention, this can be achieved by exploiting the above described light conduction through the fibers. In particular, the mineral filler may comprise a chemical compound with an element of an atomic number of at least 37 for providing a desired level of radiopacity. 
Zubni most u skladu s patentnim zahtjevom 3, naznačen time što navedeni materijal koji apsorbira rendgensko zračenje sadrži mineralno punilo koje sadrži kemijski spoj s elementom s atomskim brojem od najmanje 37, poželjnije od najmanje 57, osobito iterbijem.
The compound of Paragraph 25, wherein X41 is NR42, and R42 is selected from the group consisting of -H, a lower alkyl, a lower cycloalkyl, -C(O)N(R27)2, and -C(O)OH, wherein each R27 is independently -H or a lower alkyl. 
Spoj prema zahtjevu 19, pri čemu Xu, je NR, 1 R4, je izabran iz skupine koju čine -H, niži alkil, niži cikloalkil, - C(O)N(R27)2, 1 -C(O)OH, pri čemu svaki R2; je nezavisno -H ili niži alkil.
a processing unit which is configured to update the emission map using information of external sources, and which is configured to provide data of the emission map to an on board unit, OBU, in a car via the network interface card, which is configured to track the routes and alternative routes of the car by receiving tracking information of the car and which is configured to calculate a digital bonus for digital payment based on the selection of an alternative route bypassing an area being highly impacted by emission by the communication server, and to transfer the digital bonus to a digital account, the onboard unit, OBU, or mobile device via the network interface, to be usable for the digital payment of parking meters or public transportation by transferring the digital bonus to the parking meter or ticketing vending machine. 
- jedinicu za obradu koja je konfigurirana tako da obnavlja mapu emisije koristeći informacije vanjskih izvora i koja je konfigurirana za dostavu podataka mape emisije postavljenoj jedinici, OBU, u automobilu putem kartice mrežnog sučelja, koja je konfigurirana za praćenje ruta i alternativnih ruta automobila prihvaćanjem informacija praćenja automobila i koja je konfigurirana za izračunavanje digitalnog dobitka za digitalno plaćanje na temelju odabira alternativne rute zaobilazeći područje koje je jako zahvaćeno emisijom uz pomoć komunikacijskog poslužitelja, i za prijenos digitalnog bonusa na digitalni račun, zatim na postavljenu jedinicu, OBU, ili prijenosni uređaj putem mrežnog sučelja, kako bi
This also presents a challenge to even application. 
To isto tako stvara izazov za ravnomjerno nanošenje.
Progesterone for use in the treatment of traumatic brain injury in a human subject, said treatment comprising a constant or a two-level dosing regimen of progesterone wherein a therapeutically effective amount of progesterone is administered to said human subject by means of intravenous infusion to achieve a final progesterone serum level of about 100 ng/ml to about 1000 ng/ml. 
Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dvorazinski intravenski režim doziranja progesterona resultira razinom progesterona u serumu kod navedenog subjekta od otprilike 100 ng/ml do otprilike 2000 ng/ml.
A pharmaceutical composition comprising a nucleic acid molecule consisting of a nucleotide sequence encoding a polypeptide comprising a sequence selected from the group consisting of: SEQ. 
Farmaceutska kompozicija u skladu sa patentnim zahtjevom 13, gdje dodatna supstanca je odabrana iz grupe koja se sastoji od: masti, šećera, šećernog lanca, acetil grupe, prirodnog polimera i sintetičkog polimera.
The signal frame is parsed using the error-correction-decoded layer-1 information and the PLPs are obtained from the signal frame (S521). 
- 8521 | analiziranje okvira signala uporabom kodirano ispravljanje pogreške sloja-1 i informacije i postizanje PLP iz okvira signala
The antibody or product for use according to any one of claims 8 to 10, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, thyroid cancer, stomach cancer, liver cancer, ovarian cancer, colon cancer, breast cancer, pancreatic cancer, renal cancer, uterine cancer, melanoma, fibrosarcoma, glioblastoma, and blood cell cancer. 
Antitijelo ili proizvod za primjenu prema bilo kojem od patentnih zahtjeva 13 do 15, gdje je rak odabran iz grupe koja se sastoji od raka pluća, raka prostate, tiroidnog raka, raka želuca, raka jetre, raka jajnika, raka debelog crijeva, raka dojke, raka gušterače, raka materice, melanoma, glioblastoma, i raka krvnih stanica..
adding a compound of formula II wherein R1, R2 and R3 have the meanings as described under formula I, in the presence of an inert organic solvent to a mixture comprising an organic nitrite of formula III R4-O-N=O (III), wherein R4 is C1-C8alkyl, a compound of formula IV and an inert organic solvent; 
NH, Rz R, pri čemu Ri, R2 i R3 imaju značenja kao što je opisano pod formulom 1, u prisutnosti inertnog organskog otapala u smjesu koja sadrži organski nitrit s formulom III
The feed according to claim 15 or 16, wherein the feed is a complete feed or concentrate feed, preferably it is non-extruded and/or in the form of pellets or granulas. 
Životinjska hrana prema zahtjevima 14 ili 15, naznačeno time da je životinjska hrana potpuna životinjska hrana ili koncentrat životinjske hrane, poželjno da je neekstrudirana i/ili u obliku peleta ili granula.
wherein the catalyst is selected from the group consisting of ammonium para-toluene sulfonate, ammonium naphthalene disulfonate, ammonium sulfate, ammonium chloride, sulfuric acid, lactic acid, lead acetate, sodium acetate, calcium acetate, zinc acetate, organotin compounds, titanium esters, antimony trioxide, germanium salts, sodium hypophosphite, sodium phosphite, methane sulfonic acid and para-toluene sulfonic acid, and mixtures thereof. 
Smjesa veziva prema zahtjevu 15, gdje se katalizator izabire između amonijevog para-toluen sulfonata, amonijevog naftalen disulfonata, amonijevog sulfata, amonijevog klorida, sumporne kiseline, olovo acetata, natrij acetata, kalcij acetata, cink acetata, organotin spojeva, estera titana, trioksida antimona, soli germanija, natrij hipofosfita, natrij fosfita, metan sulfonske kiseline i para tolucn sulfonskc kiseline, i njihovih smjesa.
Systems and methods of preparing food products 
SUSTAVI I POSTUPCI ZA PROIZVODNJU PREHRAMBENIH PROIZVODA
An anti-CD20 antibody formulation comprising 20-300 mg/mL ofatumumab, wherein the formulation further comprises 10 to 100 mM sodium acetate, 25 to 100 mM sodium chloride, 0.5 to 5% arginine free base, 0.02 to 0.2 mM EDTA, 0.01 to 0.2% polysorbate 80 and adjusted to pH 5.0 to 7.0. 
Formulacija protutijela anti-CD20, naznačena time, da obuhvaća od 20 do 300 mg/mL ofatumumaba, pri čemu formulacija nadalje obuhvaća od 10 do 100 mM natrijevog acetata, od 25 do 100 mM natrijevog klorida, od 0,5 do 5% slobodne baze arginina, od 0,02 do 0,2 mM EDTA, od 0,01 do 0,2% polisorbata 80, i podešava se na pH-vrijednost od 5,0 do 7,0. [image]
Thus it is possible for a shop to insert the security member e.g. on arrival of the product. 
Na taj je način moguće za trgovinu umetnuti zaštitni član, na primjer, pri dolasku proizvoda.
The compound for use according to claim 8 wherein the viral infection is caused by Hepatitis C virus. 
Tvar za uporabu u skladu s patentnim zahtjevom 8 pri čemu je virusna infekcija uzrokovana virusom hepatitisa C.
The use according to Claim 9 or Claim 10, wherein at least one cut-off wavelength of a passband in the spectral separation filters is red-shifted compared to a corresponding wavelength in at least one of the spectrally separated images to be viewed. 
Uporaba prema zahtjevu 11 ili zahtjevu 12, naznačena time što je barem jedna odsječena valna duljina prolaznog pojasa u filtrima za razdvajanje spektra crveno pomaknuta u usporedbi s odgovarajućom valnom duljinom u barem jednoj od spektralno odijeljenih slika za pregledavanje.
and red phosphorus (4.5 g.) and the resulting mixture stirred at reflux for 16 hours. 
i crvenim fosforom (4.5 g.) i dobivena smjesa se miješa na refluksu 16 sati.
Following, in the conditioning equipment 68, the glued beam-like block of wood was heated in water having a temperature of approximately 80 °C for a period of approximately 2.5 days, and was subsequently sliced to veneer 14 having a thickness of approximately 0.65 mm. 
Nakon toga se u opremi za kondicioniranje 68 slijepljeni blok od drva koji ima oblik grede zagrijavao u vodi koja je imala temperaturu od približno 80%C, kroz vremensko razdoblje od približno 2.5 dana, i nakon toga je blok bio rezan na kriške u furnir 14 koji ima debljinu od približno 0.65 mm.
not less than 80% of the metformin or a pharmaceutically acceptable salt thereof is released after 19 hours; and not less than 85% of the metformin or a pharmaceutically acceptable salt thereof is released after 24 hours. 
75-85% metformina ili njegove farmaceutski prihvatljive soli se oslobađa nakon 16 sati; ne manje od 80% metformina ili njegove farmaceutski prihvatljive soli se oslobađa nakon 19 sati; i ne manje od 85% metformina ili njegove farmaceutski prihvatljive soli se oslobađa nakon 24 sata.
Y represents a carbonyl group or a methylene group optionally substituted by a hydroxyl group; and/or p represents 2 and q represents 0; and more particularly wherein R1, R2, R3, X, Y, p, q, m, o and n are as defined here-above. 
Y predstavlja karbonilnu skupinu ili metilensku skupinu, izborno supstituiranu s hidroksilnom skupinom; i/ili p znači 2, a q znači 0; specifičnije gdje R1, R2, R3, X, Y, p, q, m, oin su definirani kao gore.
The humanized CD37-specific binding protein according to claim 1, wherein the light chain CDR1, CDR2, and CDR3 consist of the amino acid sequences of SEQ ID NOS: 61, 64 and 66, respectively; and wherein the heavy chain CDR1, CDR2, and CDR3 consist of the amino acid sequences of SEQ ID NOS:63, 65 and 67 respectively. 
Humanizirani CD37-specifični vezni protein u skladu s patentnim zahtjevom 1, pri čemu se CDR1, CDR2 i CDR3 lakog lanca sastoje od sljedova aminokiselina SEQ ID NOS: 61, 64 i 66, redom; i pri čemu se CDR1, CDR2 i CDR3 teškog lanca sastoje od sljedova aminokiselina SEQ ID NOS: 63, 65 i 67, redom.
A modified soluble FGF receptor Fc fusion of claim 30 wherein said wherein said cancer is selected from the group of melanoma, leukemia, renal cancer, colon cancer, ovarian cancer, prostate cancer, lung cancer, bladder cancer, breast cancer, and head and neck cancer. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 37, naznačena time što se navedeni rak bira iz skupine koju čine melanom, leukemija, rak bubrega, rak debelog crijeva, rak jajnika, rak prostate, rak pluća, rak mokraćnog mjehura, rak dojke, te rak glave i vrata.
A spontaneously dispersible pharmaceutical composition as claimed in any preceding claim comprising 0.05 to 20% by weight of 7-t-butoxyiminomethylcamptothecin, 5 to 85 % by weight of a lipophilic component, 5 to 90 % by weight of a surfactant, 0.00 to 20% of a co-solvent, and 5 to 60 % by weight of a hydrophilic component, all weights based on the total composition. 
Spontano disperzibilni farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži 0,05 do 20%, težinski, 7-t-butoksiiminometilkamptotecina, 5 do 85%, težinski, lipofilne komponente, 5 do 90%, težinski, surfaktanta, 0,00 do 20% suotapala, te 5 do 60%, težinski, hidrofilne komponente, gdje se sve težine baziraju na ukupnom pripravku.
The combination of claim 20 wherein the other therapeutic agent is a corticosteroid, an antichlolinergic agent, or a PDE4 inhibitor. 
Kombinacija iz patentnog zahtjeva 20 naznačena time, da je drugo terapijsko sredstvo kortikosteroid, antikolinergijsko sredstvo ili inhibitor PDE4.
Combination of different materials from each group can be combined in defined ratio. 
Kombinacija različitih materijala iz svake grupe može se kombinirati u različitom omjeru.
In a particularly preferred embodiment the present invention relates to a method, wherein the liver disease is hepatitis, cirrhosis, inborn errors of metabolism, acute liver failure, acute liver infections, acute chemical toxicity, chronic liver failure, cholangiocitis, biliary cirrhosis, Alagille syndrome, alpha-l-antitrypsin deficiency, autoimmune hepatitis, biliary atresia, cancer of the liver, cystic disease of the liver, fatty liver, galactosemia, gallstones, Gilbert's syndrome, hemochromatosis, hepatitis A, hepatitis B, hepatitis C and other hepatitis viral infections, poryphyria, primary sclerosing cholangitis, Reye's syndrome, sarcoidosis, tyrosinemia, type 1 glycogen storage disease or Wilson's disease. 
Mikrokapsula prema zahtjevu 16, naznačena time da bolest jetre je hepatitis, ciroza, prirođene greške metabolizma, akutno zatajenje jetre, akutne infekcije jetre, akutna kemijska toksičnost, kronično zatajanje jetre, kolangiocitis, bilijarna ciroza, Alagilleov sindrom, nedostatak alfa-1-antitripsina, autoimuni hepatitis, bilijarna atrezija, rak jetre, cistična bolest jetre, masna jetra, galaktozemija, žučni kamenci, Gilbertov sindrom, hemokromatoza, hepatitis A, hepatitis B, hepatitis C i druge virusne infekcije hepatitisom, porifirija, primarni sklerozni kolangitis, Reyeov sindrom, sarkoidoza, tirozinemija, bolest pohrane glikogena tip 1 ili Wilsonova bolest.
The phases were separated and the aqueous phase was washed with methylene chloride (25 ml) and filtered clear (Celite). 
Faze su razdvojene i vodena faza je oprana s metilen kloridom (25 ml) i bistro filtrirana (Celit).
In a further embodiment of the method for the immunological determination of an antibody against the amyloid B peptide in a sample the immunoassay comprises the amyloid B peptide conjugated to a solid phase, an anti-idiotype antibody against an antibody against the amyloid B peptide conjugated to digoxygenin as detectable label, and a detection antibody against digoxygenin conjugated to horseradish peroxidase. 
Postupak za imunološko određivanje protutijela za amiloid-B-peptid, naznačen time, da se provodi u uzorku uporabom imunološke analize koja se primjenjuje na protutijelu koje se dobiva iz stanične linije DSM ACC2939, pri čemu imunološka analiza obuhvaća amiloid-f-peptid konjugiran na krutu fazu, anti-idiotipično protutijelo koje je protiv protutijela za amiloid-B-peptid, dobiveno iz stanične linije DSM ACC2939, konjugirano na digoksigenin koji služi kao oznaka koja se može otkrivati, te protutijelo za otkrivanje protiv digoksigenina, konjugirano na peroksidazu.
The cap 1500, 1600 contains a generally planar top surface 1502, 1603 and at least one sidewall 1503, 1604 . 
Poklopac 1500, 1600 obično je planarne gornje površine 1502, 1603 i s najmanje jednom bočnom stijenkom 1503, 1604.
The immunogenic suspension or solution of the invention comprises a stabilizer, which may comprise (i) a final concentration of about 1% to about 5% w/v of a mixture of two reducing monosaccharides, (ii) a final concentration of about 0.1% to about 0.3% w/v of at least one acid antioxidant, and (iii) a final concentration of about 0.5% to about 7.5% w/v of at least one bulking agent. 
(a) (1) konačnu koncentraciju od oko 1% do oko 5% tež.Avol. smjese dva redukcijska monosaharida, (ii) konačnu koncentraciju od oko 0.1% do oko 0.3% tež./vol. najmanje jednog kiselog antioksidansa, i (iii) konačnu koncentraciju od oko 0.5% do oko 7.5% tež.Avol. najmanje jednog punila ili
R12 H, alkyl group such as a methyl or ethyl group, olefinic or aromatic or may 
H, alkil skupina kao što je metil ili etil skupina, olefinska ili aromatska skupina ili može posebno biti: zombi
In another embodiment, the antibody or antigen binding fragment thereof promotes bone deposition. In another embodiment, the antibody or antigen binding fragment thereof improves the function of a non-skeletal organ affected by OI selected from the group consisting of hearing function, lung function, and kidney function. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što protutijelo ili njegov ulomak koji veže antigen poboljšava funkciju ne-skeletnog organa koji je pogođen s OI odabranim iz skupine koja se sastoji od funkcije sluha, funkcije pluća, i funkcije bubrega.
Accordingly the inventions in a first aspect relates to a method for production of a coating on a solid substrate comprising the steps of applying a liquid coating composition comprising 
S tim u skladu, izum se u prvom obliku odnosi na postupak za proizvodnju prevlaka na krutoj podlozi koji postupak obuhvaća stupanj - < nanošenja tekućeg premaza koji sadrži dodataka,
The starting material, i.e. r-hIL-18BP post CM, was then loaded onto the column. 
Početni materijal tj. r-hTL-18BP nastalo nakon CM-a, bio je nanesen na kolonu.
The phases were separated and the organic layer was evaporated to give the title compound (409 mg, 79%) as a yellow oil which was a mixture of diastereomers. 
Faze se razdvoji, a organski sloj otpari kako bi se dobilo naslovni spoj (409 mg, 79 %) u obliku žutog ulja, koje je smjesa dijastereomera.
Expression in insect cells 
Ekspresija u stanicama kukaca
A 5-D-fructose dehydrogenase for use according to claim 11 wherein said composition of matter further comprises a glucose isomerase. 
-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 11, naznačena time, da spomenuti sastav tvari također sadrži glukoza izomerazu.
The polymer hydrogel of item 45 wherein the weight ratio of carboxymethylcellulose to hydroxyethylcellulose is about 3. 
Polimerni hidrogel u skladu s patentnim zahtjevom 3, naznačen time da je težinski omjer karboksimetilceluloze naspram hidroksietilceluloze u vodenoj otopini veći od 1:1.
In certain embodiments, when the RH is increased from about 0% to about 95% RH, Form D exhibits a mass change of less than about 5%, e.g., about 4%, of the starting mass of the sample. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što čvrsti oblik pokazuje povećanje mase manje od otprilike 0,5% kada se podvrgne povećanju relativne vlažnosti od otprilike 0% do otprilike 95% relativne vlažnosti.
the height of the downstream portion being sufficiently large to facilitate passage therethrough of said blood cells and sufficiently small to inhibit passage therethrough of said CTCs, and 
Uređaj prema patentnom zahtjevu 1, pri čemu visina donjeg dijela sprečava prolaz cirkulirajućim stanicama tumora i olakšava prolaz crvenim krvnim zrncima čovjeka.
A compound of Claim 1, wherein R1 is selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted aryl, 
Spoj prema Zahtjevu 1, naznačen time, da R, je odabran iz skupine koja sadrži (1) supstituirani i nesupstituirani alkil,
The key as defined in claim 32, wherein the inner wall (124) of said longitudinal profile groove and the adjoining longitudinal pocket (135) are located at a depth from said side surface (123) of the key blade (120) which is greater than half the thickness of said key blade. 
Ključ kako je definiran u zahtjevu 1, naznačen time da su unutarnja stjenka navedenog uzdužnog profila utora i susjedni uzdužni džep smješteni na dubini od navedene bočne površine oštrice ključa koja je veća od polovine debljine navedene oštrice ključa.
Alternatively, or additionally, the at least one guide element is provided on a further roof element, relative to which further roof element the movable roof element is nestable. 
Autobus u skladu s patentnim zahtjevom 3, naznačen time što tijelo sadrži najmanje jedan vodeći element, duž kojeg se vodi pokretni krovni element prilikom svog gibanja.